NAPLEX - Osteoporosis

3. Carries a black box warning for osteosarcoma
6. Lower efficacy than first-line agents, may be beneficial for breast cancer, and increases the risk for DVT/stroke
10. Monoclonal antibody that targets RANKL and prevents activating RANK which is important in activating the action of osteoclasts; thus reducing bone resorption and increasing bone strength (brand name)
11. Brand name bisphosphonate that has an IV and oral formulation
12. Scoring system that includes clinical risk factors and is used to determine if a patient should begin osteoporosis therapy
13. Stimulates estrogen receptors selectively in bone tissue leading to an increase in bone strength (brand name)
16. Abbreviation for potential complication in patients taking zoledronic acid
17. Important supplement to consider in osteoporotic patients
18. Rare adverse effect of bisphosphonates that affects the jaw
19. This form of calcium is better absorbed than carbonate
20. Twice yearly injection that can cause low calcium and muscle pain as adverse effects

1. Brand name medication that has anabolic (bone-building) effects by stimulating osteoblasts
2. Class of medication that is most often used first-line for osteoporosis
4. Beneficial for osteoporosis but avoided due to the risk of cancer and blood clots
5. Scan that assesses bone mineral density
7. Potential toxicity associated with zoledronic acid
8. Opposes the action of parathyroid hormone and inhibits the activity of osteoclasts which results in an increase in bone strength
9. This medication inhibits osteoclasts; osteoclasts breakdown bone to help pull calcium into the bloodstream
14. A value of -2.5 or lower is indicative of osteoporosis with this assessment
15. Nasal spray that can help with osteoporosis and compression fracture pain